Overview

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

Status:
Completed

Trial end date:
2018-05-29

Target enrollment:

Participant gender:

Summary

Evaluation of safety and efficacy of iron isomaltoside/ferric derisomaltose compared with iron sucrose, in subjects with both non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA).

Phase:

Phase 3

Details

Lead Sponsor:

Pharmacosmos A/S

Treatments:

Ferric Compounds
Ferric Oxide, Saccharated
Iron
Iron isomaltoside 1000